GIANNOULIA, PANAGIOTA
 Distribuzione geografica
Continente #
NA - Nord America 307
EU - Europa 263
AS - Asia 121
AF - Africa 25
OC - Oceania 1
SA - Sud America 1
Totale 718
Nazione #
US - Stati Uniti d'America 307
GB - Regno Unito 75
SE - Svezia 54
CN - Cina 37
VN - Vietnam 32
IT - Italia 30
SG - Singapore 25
DE - Germania 23
IE - Irlanda 16
CH - Svizzera 14
IN - India 14
TG - Togo 12
RU - Federazione Russa 11
FR - Francia 9
EE - Estonia 8
BG - Bulgaria 7
CI - Costa d'Avorio 7
JO - Giordania 7
UA - Ucraina 7
ZA - Sudafrica 5
IR - Iran 4
GR - Grecia 3
BE - Belgio 2
FI - Finlandia 2
MY - Malesia 2
CL - Cile 1
NL - Olanda 1
NZ - Nuova Zelanda 1
RO - Romania 1
SC - Seychelles 1
Totale 718
Città #
Southend 73
Chandler 65
Dong Ket 32
Singapore 23
Fairfield 20
Santa Clara 17
Dublin 16
Wilmington 16
Houston 14
Princeton 14
Seattle 14
Bern 13
Cambridge 12
Lomé 12
Woodbridge 11
Ashburn 10
New York 10
Abidjan 7
Amman 7
Padova 7
Sofia 7
Turin 7
Westminster 7
Ann Arbor 6
Jacksonville 6
Medford 5
Tianjin 5
Boardman 4
Nanjing 4
Saint Petersburg 4
Hebei 3
Olalla 3
Redwood City 3
Rome 3
Beijing 2
Bremen 2
Brussels 2
Changsha 2
Florence 2
Helsinki 2
Jinan 2
Kish 2
Milan 2
Rawang 2
Shenyang 2
Andover 1
Auckland 1
Falls Church 1
Fuzhou 1
Groningen 1
Guangzhou 1
Henderson 1
Kunming 1
La Canada Flintridge 1
Lausanne 1
Leawood 1
Los Angeles 1
Mahé 1
Moscow 1
Orange 1
Parma 1
Qingdao 1
San Diego 1
San Mateo 1
Suceava 1
Suzhou 1
Weifang 1
Wenzhou 1
Wuhan 1
Zanjan 1
Totale 507
Nome #
The Bcr-Abl kinase promotes aberrant expression of spliced oncogenic Ikaros isoforms in Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with tyrosine kinase inhibitors 123
Presence or the Emergence of a F317L BCR-ABL Mutation May Be Associated With Resistance to Dasatinib in Philadelphia Chromosome Positive Leukemia 119
null 104
Innovative phase I-II study of concomitant and consecutive treatment with Dasatinib and MK-0457 in refractory Ph+ CML and ALL patients 99
High-resolution genomic profiling of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) patients identified novel recurrent copy number variations involved in both pathogenesis and resistance to tyrosine kinase inhibitors 85
Genome wide analysis of Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL) reveals a recurring deletion of VPREB1 gene which affects B-cell differentiation 81
New drugs to overcome meccanisms of resistance in Ph+ leukemia: Bosutinib 80
Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain 48
Totale 739
Categoria #
all - tutte 1.700
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.700


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202082 0 0 0 0 8 9 13 20 14 6 8 4
2020/202180 17 3 0 1 1 6 0 2 5 3 1 41
2021/2022143 6 7 7 19 10 9 4 10 3 12 29 27
2022/2023208 22 40 7 27 13 14 4 9 34 3 20 15
2023/202443 1 6 2 6 4 18 0 0 0 1 1 4
2024/202568 6 18 11 9 24 0 0 0 0 0 0 0
Totale 739